La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Novozymes Bilan de santé

Santé financière contrôle des critères 4/6

Novozymes possède un total de capitaux propres de DKK14.4B et une dette totale de DKK7.4B, ce qui porte son ratio d'endettement à 51.6%. Son actif total et son passif total sont DKK28.4B et de DKK14.0B. L'EBIT de Novozymes est DKK4.5B ce qui fait que son ratio de couverture des intérêts 53.8. Elle dispose de liquidités et de placements à court terme de DKK1.1B.

Informations clés

51.6%

Ratio d'endettement

DKK 7.41b

Dette

Ratio de couverture des intérêts	53.8x
Argent liquide	DKK 1.12b
Fonds propres	DKK 14.35b
Total du passif	DKK 14.04b
Total des actifs	DKK 28.39b

Mises à jour récentes de la santé financière

Pas de mise à jour

Recent updates

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de NSIS N ( DKK9.5B ) dépassent ses passifs à court terme ( DKK7.3B ).

Passif à long terme: Les actifs à court terme de NSIS N ( DKK9.5B ) dépassent ses passifs à long terme ( DKK6.8B ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de NSIS N ( 43.9% ) est considéré comme élevé.

Réduire la dette: Le ratio d'endettement de NSIS N est passé de 28.5% à 51.6% au cours des 5 dernières années.

Couverture de la dette: La dette de NSIS N est bien couverte par le flux de trésorerie opérationnel ( 56% ).

Couverture des intérêts: Les paiements d'intérêts de NSIS N sur sa dette sont bien couverts par l'EBIT ( 53.8 x couverture).

Novozymes Bilan de santé

Santé financière contrôle des critères 4/6

Informations clés

Mises à jour récentes de la santé financière

Recent updates

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Less than half of directors are independent

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

Investor sentiment improves as stock rises 18%

Less than half of directors are independent

Novozymes Launches ProSilience™ HU58

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Novozymes A/S Announces Change to the Executive Leadership Team

First quarter 2023 earnings released: EPS: kr.2.83 (vs kr.3.00 in 1Q 2022)

Less than half of directors are independent

Investor sentiment deteriorates as stock falls 17%

Less than half of directors are independent

Novozymes A/S Provides Earnings Guidance for the Year 2023

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Less than half of directors are independent

Third quarter 2022 earnings released

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

Less than half of directors are independent

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Less than half of directors are independent

Second quarter 2022 earnings released: EPS: kr.2.92 (vs kr.2.85 in 2Q 2021)

Less than half of directors are independent

Novozymes A/S Provides Earnings Guidance for the Year 2022

Novozymes A/S to Report Nine Months, 2023 Results on Oct 26, 2023

Novozymes Extends the Lifetime of Textiles with Sustainable Innovation

Less than half of directors are independent

First quarter 2022 earnings released: EPS: kr.3.00 (vs kr.3.17 in 1Q 2021)

Less than half of directors are independent

Novozymes A/S Raises Full-Year Financial Guidance for 2022

Less than half of directors are independent

Upcoming dividend of kr.5.50 per share

Less than half of directors are independent

Less than half of directors are independent

Novozymes A/S Provides Revenue Guidance for 2022

Less than half of directors are independent

Novozymes A/S (CPSE:NZYM B) completed the acquisition of a 60% stake in Synergia Life Sciences Pvt. Ltd. for DKK 1 billion.

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Novozymes A/S Provides Earnings Guidance for the Full Year 2021

First quarter 2021 earnings released: EPS kr.3.17 (vs kr.2.89 in 1Q 2020)

Novozymes A/S Reaffirms Sales Guidance for the Year 2021

Univar Solutions and Novozymes® Partner to Bring Innovative, Sustainable Biotechnology Products to Customers in the United States and Canada

Novozymes Acquires Data Science Platform of Biota to Strengthen Microbiome R&D Capabilities in Probiotic Development

Novozymes A/S (CPSE:NZYM B) acquired the Microbiome R&D Team and Data Science Platform from Biota Technology, Inc.

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Découvrir des entreprises saines